Switch theme
Sign up to access all valuation multiples
MariMed Inc is a multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Its award-winning portfolio of cannabis brands, including Betty's Eddies, Bubby’s Baked, Vibations, InHouse, and Nature’s Heritage, sets the company apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry.
2011
832
LTM Revenue $161M
LTM EBITDA $19.9M
$113M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MariMed has a last 12-month revenue (LTM) of $161M and a last 12-month EBITDA of $19.9M.
In the most recent fiscal year, MariMed achieved revenue of $158M and an EBITDA of $13.8M.
MariMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MariMed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $161M | XXX | $158M | XXX | XXX | XXX |
| Gross Profit | $64.0M | XXX | $62.9M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $19.9M | XXX | $13.8M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $3.8M | XXX | $3.5M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | -$13.7M | XXX | -$12.2M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $67.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MariMed's stock price is $0.
MariMed has current market cap of $32.7M, and EV of $113M.
See MariMed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $32.7M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MariMed has market cap of $32.7M and EV of $113M.
MariMed's trades at 0.7x EV/Revenue multiple, and 8.2x EV/EBITDA.
Equity research analysts estimate MariMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MariMed has a P/E ratio of -2.4x.
See valuation multiples for MariMed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.7M | XXX | $32.7M | XXX | XXX | XXX |
| EV (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 5.7x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBIT | 29.7x | XXX | 32.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.4x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | -26.7x | XXX | -19.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMariMed's last 12 month revenue growth is 7%
MariMed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
MariMed's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MariMed's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MariMed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascend Wellness Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Ayr Wellness | XXX | XXX | XXX | XXX | XXX | XXX |
| Cresco Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Grown Rogue | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MariMed acquired XXX companies to date.
Last acquisition by MariMed was XXXXXXXX, XXXXX XXXXX XXXXXX . MariMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MariMed founded? | MariMed was founded in 2011. |
| Where is MariMed headquartered? | MariMed is headquartered in United States of America. |
| How many employees does MariMed have? | As of today, MariMed has 832 employees. |
| Who is the CEO of MariMed? | MariMed's CEO is Mr. Robert Fireman. |
| Is MariMed publicy listed? | Yes, MariMed is a public company listed on PINX. |
| What is the stock symbol of MariMed? | MariMed trades under MRMD ticker. |
| When did MariMed go public? | MariMed went public in 2012. |
| Who are competitors of MariMed? | Similar companies to MariMed include e.g. Live Verdure, Ascend Wellness Holdings, Ayr Wellness, Cresco Labs. |
| What is the current market cap of MariMed? | MariMed's current market cap is $32.7M |
| What is the current revenue of MariMed? | MariMed's last 12 months revenue is $161M. |
| What is the current revenue growth of MariMed? | MariMed revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of MariMed? | Current revenue multiple of MariMed is 0.7x. |
| Is MariMed profitable? | Yes, MariMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MariMed? | MariMed's last 12 months EBITDA is $19.9M. |
| What is MariMed's EBITDA margin? | MariMed's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of MariMed? | Current EBITDA multiple of MariMed is 5.7x. |
| What is the current FCF of MariMed? | MariMed's last 12 months FCF is -$4.2M. |
| What is MariMed's FCF margin? | MariMed's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of MariMed? | Current FCF multiple of MariMed is -26.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
